BNP Paribas Financial Markets
MAZE

BNP Paribas Financial Markets’s Maze Therapeutics MAZE Stock Holding History

BNP Paribas Financial Markets’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Buy
77,251
+70,776
+1,093% +$1.86M ﹤0.01% 2700
2026
Q1 		$193K Buy
6,475
+1,002
+18% +$44.2K ﹤0.01% 4069
2025
Q4 		$227K Sell
5,473
-6,545
-54% -$225K ﹤0.01% 4007
2025
Q3 		$312K Buy
12,018
+11,259
+1,483% +$190K ﹤0.01% 3796
2025
Q2 		$9.31K Buy
759
+359
+90% +$3.73K ﹤0.01% 4859
2025
Q1 		$4.4K Buy
+400
New +$4.82K ﹤0.01% 4873

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

BNP Paribas Financial Markets's MAZE Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Maze Therapeutics (MAZE) stake by 1,093% in Q2 2026, buying an estimated $1.86M and bringing the position to 77,251 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2700.

BNP Paribas Financial Markets first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 151 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • BNP Paribas Financial Markets held 77,251 shares of Maze Therapeutics worth $2.31M as of Q2 2026.
  • BNP Paribas Financial Markets bought 70,776 Maze Therapeutics shares in Q2 2026, an estimated $1.86M.
  • Maze Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2700 holding.
  • BNP Paribas Financial Markets first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 151 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.